The two types of uterine cancer are endometrial cancer and uterine sarcoma. Each of these types has several subtypes.

GSK’s Jemperli has been cleared for routine use by the NHS as a first-line treatment for hundreds of women with dMMR/MSI-H endometrial cancer.

GSK's PD-1 inhibitor Jemperli improves overall survival when used first-line in an all-comer endometrial cancer trial.